Avast Therapeutics

Executive Summary

Avast Therapeutics is a private biotechnology company headquartered in San Diego, California, founded in 2019 with a mission to develop novel small molecule therapies for neurodegenerative diseases. The company addresses significant unmet medical needs in a challenging therapeutic area characterized by limited treatment options and high patient burden. By leveraging its expertise in small molecule discovery, Avast aims to advance a pipeline of drug candidates targeting key pathways involved in neurodegeneration, such as protein aggregation, neuroinflammation, and oxidative stress. While the company remains in early stages of development and has not yet disclosed specific pipeline programs, its focus on innovative small molecule approaches positions it within a competitive landscape of companies seeking to modify disease progression in Alzheimer's, Parkinson's, and related disorders. Avast's ability to progress candidates through preclinical development and into clinical trials will be critical for its future success and valuation. The company's private status and limited public disclosures suggest it is still in the preclinical or early clinical phase, with potential for partnerships or funding rounds to support advancement.

Upcoming Catalysts (preview)

• Q2 2027Lead Program IND Filing25% success
• Q4 2026Preclinical Data Presentation70% success
• Q3 2026Series A or B Financing Announcement50% success